AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.71B
1-Year Est. Return
374.45%
This Fund
S&P 500
1 Year Est. Return
+374.45%
AUM
$1.71B
AUM Growth
+$313M
(+23%)
Holding
118
Top Buys
| 1 | +$28.3M | |
| 2 | +$26.6M | |
| 3 | +$20.4M | |
| 4 |
Xenon Pharmaceuticals
XENE
|
+$19.6M |
| 5 |
Erasca
ERAS
|
+$17.1M |
Top Sells
| 1 | +$58.6M | |
| 2 | +$16.9M | |
| 3 | +$14.8M | |
| 4 |
ACLX
Arcellx
ACLX
|
+$14.2M |
| 5 |
BridgeBio Pharma
BBIO
|
+$12.3M |
Sector Composition
| 1 | Healthcare | 97.1% |
| 2 | Financials | 0.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
ImmunityBio
IBRX
$7.52B
| – | – |
0
|
|
||
102
Moderna
MRNA
$19.5B
| – | – |
0
|
|
||
|
MRSN
103
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-100,000
|
|
||
|
NVO
104
Novo Nordisk
NVO
$186B
| – | – |
0
|
|
||
105
uniQure
QURE
$1.88B
| – | – |
-50,000
|
|
||
106
Ultragenyx Pharmaceutical
RARE
$2.21B
| – | – |
-75,000
|
|
||
107
Arcus Biosciences
RCUS
$3B
| – | – |
-300,000
|
|
||
108
Summit Therapeutics
SMMT
$11.7B
| – | – |
0
|
|
||
109
State Street SPDR S&P 500 ETF Trust
SPY
$781B
| – | – |
0
|
|
||
110
Tango Therapeutics
TNGX
$3.11B
| – | – |
-1,000,000
|
|
||
|
VTYX
111
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-6,484,558
|
|
||
112
State Street SPDR S&P Biotech ETF
XBI
$7.9B
| – | – |
0
|
|
||
113
State Street Health Care Select Sector SPDR ETF
XLV
$37.8B
| – | – |
0
|
|
||
|
PCSC
114
Perceptive Capital Solutions
PCSC
$123M
| – | – |
-50,000
|
|